anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this prospective randomized controlled study, 100 patients with NSAIDS-related intestinal mucosal injury will be enrolled in 10 clinical centers across China from July 2021 to December 2022. All patients who met the inclusion criteria and agreed to participate in the study underwent baseline capsule endoscopy. Patients with intestinal mucosal injury detected during the initial capsule endoscopy were randomly divided into isoladin maleate group or magnesium aluminum carbonate control group using computer-generated random numbers. Patients in the isoladine maleate group received 4 mg isoladine maleate (Gesellon, Japan) every morning for 4 weeks (or 8 weeks, duration to be determined); Magnesium aluminum carbonate control group received 1 g magnesium aluminum carbonate every morning, afternoon and evening for 4 weeks (or 8 weeks, course to be determined). After treatment, capsule endoscopy was performed again to evaluate the healing of intestinal mucosa. Laboratory tests including blood routine, stool routine, and occult blood were performed at the beginning and end of the study. Abdominal symptoms and signs were assessed by two experienced clinicians at week 0, 1, 2, and 4 (8) of the study.
Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
1. A composition comprising at least of a 70% biologically-active receptor immunoglobulin hybrid protein (protein Ig fusion) culturing a host transformed with DNA encoding the protein-Ig fusion in a culture system having a low temperature of about 27 degree C to about 32 degree C, wherein protein-Ig fusion comprises a member of the TNF receptor family. 2. The composition of claim 1 wherein said TNF receptor family member is TNFR-55, HVEM or a fragment thereof. 3. The composition of claim 1 wherein at least one cysteine residue of the TNF family domain is replaced with alanine thereby increasing the yield of active forms of fusion expressed. 4. The composition of claim 1 wherein the protein-Ig fusion is a lymphotoxin-beta (LT-beta-R). 5. The composition of claim 1 wherein cysteines are replaced by alanines at positions 101 and 108 of the LT-beta-R. 6. A method making a preparation of any one of claims 1-5 comprising culturing a host in a mammal transformed with DNA encoding the protein-Ig fusion in a culture system having a temperature of about 27 degree C to about 35 degree C. 7. The method of claim 6 wherein the temperature is about 27 degree C to about 32 degree C. 8. The method of claim 6 wherein said transformed host is first cultured at a temperature above about 33 degree C for a period of time sufficient to allow growth of said host. 9. The method of claim 6 wherein comprising recovering fusions by hydrophobic interaction chromatography. 10. A pharmaceutical preparation obtained by (a) culturing a host transformed with DNA encoding the protein-Ig fusion in a culture system having a temperature of about 27 degree C to about 32 degree C, wherein the protein-Ig fusion comprises a member of the TNF family thereby expressing active protein-Ig fusions; (b) recovering active protein-Ig fusions from said culture system; and (c) combining the active protein-Ig fusions of step (b) with a pharmaceutically acceptable carrier. 11. The pharmaceutical preparation of claim 10 wherein the protein-Ig fusion comprises a lymphotoxin-beta receptor or a fragment thereof. 12. The pharmaceutical preparation of claim 10 wherein the protein-Ig fusion comprises HVEM. 13. A composition comprising an active protein-Ig fusion obtained by culturing yeast transformed with DNA encoding the fusion in a culture system having a temperature of about 10 degree C to about 25 degree C. 14. The composition of claim 13 wherein said fusion comprising a member of the TNF family. 15. The composition of claim 13 wherein said fusion comprising a lymphotoxin-beta receptor or a fragment thereof. 16. The composition of claim 13 wherein said fusion comprising HVEM, or a fragment thereof.
Samfilcon A multifocal toric contact lenses worn first, with lehfilcon A multifocal toric contact lenses worn second. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 2 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
PURPOSE: Breast cancer is an important health problem, like obesity and dyslipidemia, with a strong association between body mass index (BMI) and breast cancer incidence and mortality. The risk of breast cancer is also high in women with high mammographic breast density (MBD). The purpose of this study was to analyze the association between BMI and MBD according to breast cancer molecular subtypes.
METHODS: This transversal, descriptive, multicenter study was conducted at three Spanish breast cancer units from November 2019 to October 2020 in women with a recent diagnosis of early breast cancer. Data were collected at the time of diagnosis.
RESULTS: The study included 162 women with a recent diagnosis of early breast cancer. The median age was 52 years and 49.1% were postmenopausal; 52% had normal weight, 32% overweight, and 16% obesity. There was no association between BMI and molecular subtype but, according to menopausal status, BMI was significantly higher in postmenopausal patients with luminal A (p = 0.011) and HER2-positive (p = 0.027) subtypes. There was no association between MBD and molecular subtype, but there were significant differences between BMI and MBD (p < 0.001), with lower BMI in patients with higher MBD. Patients with higher BMI had lower HDL-cholesterol (p < 0.001) and higher insulin (p < 0.001) levels, but there were no significant differences in total cholesterol or vitamin D.
CONCLUSIONS: This study showed higher BMI in luminal A and HER2-positive postmenopausal patients, and higher BMI in patients with low MBD regardless of menopausal status.
Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
Acne vulgaris (acne) is a highly prevalent inflammatory skin disease, especially in adolescents and young adults. Acne is estimated to affect 231 million people worldwide, therefore being one of the most prevalent diseases globally. Acne is also one of the top causes of years lived with disability and nonfatal disease burden. Despite being one of the most prevalent diseases worldwide, the mainstays of acne treatment have remained largely unchanged over the past 30 years. To date there is still no effective treatment that can prevent and cure this disease.

The aim of this first-in-human (FIH), Phase I/II trial is to evaluate the safety, efficacy and immunogenicity of the Acne mRNA vaccine candidate at three different dose levels in adults aged 18 to 45 years with moderate to severe acne. The study is designed to assess the safety profile and efficacy (also long-term) of the vaccine candidate, select the dose for the further clinical development steps and to describe the immunogenicity profile of the vaccine.
The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.

HIV-infected patients with Karnofsky scores at least 80 (with or without documented recurrent herpes group infections) are successively entered into consecutively studied, escalating dose cohorts. There are a total of 4 dose cohorts of FIAU and each patient takes the required amount of FIAU syrup every 8 hours, 1 hour prior to or 3 hours after meals, for a total of 14 days. Entry of new patients at the next higher dose is based on results of tolerance and safety data for prior cohort when all 10 have received 14 days of therapy and at least 7 have met all of the tolerance criteria. Although not formally randomized due to the sequential nature of the study and serious medical condition of the patients, every attempt to avoid bias in assigning a patient to a dose is made. Patients are entered starting with the first dose cohort. Upon meeting the enrollment and tolerance criteria for dose escalation, up to 5 patients with a history of chronic HBV infection and surface antigen positive at their screening visit are added to the end of each dose cohort. Plasma samples are taken to determine peak and trough levels of FIAU at Days 1, 3, 7, and 14 or at last visit. Patients with ongoing active infections are followed by culture (HSV, VZV and CMV) or test (HBV) at Days 1, 3, 7, and 14. Antiemetic therapy with Reglan, Compazine, and Trilafon is given concomitantly at the discretion of the investigator and tolerance determined with antiemetic therapy ongoing. Patients are advised to avoid heavy exercise within 24 hours of any laboratory tests.
Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. It is recommended that patients with impaired hepatic function be carefully monitored when taking itraconazole. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolized by CYP3A4.

In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with itraconazole is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. It is recommended that liver function monitoring be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications (see CLINICAL PHARMACOLOGY: Special Populations and DOSAGE AND ADMINISTRATION).
PURPOSE: Programmed death receptor ligand-1 (PD-L1) expression and tumor mutational burden (TMB) are approved screening biomarkers for immune checkpoint inhibition (ICI) in advanced triple negative breast cancer. We examined these biomarkers along with characterization of the tumor microenvironment (TME) between breast tumors (BrTs), axillary metastases (AxMs), liver metastases (LvMs), non-axillary lymph node metastases, and non-liver metastases to determine differences related to site of metastatic disease.
METHODS: 3076 unpaired biopsies from breast cancer patients were analyzed using whole transcriptome sequencing and NextGen DNA depicting TMB within tumor sites. The PD-L1 positivity was determined with VENTANA PD-L1 (SP142) assay. The immune cell fraction within the TME was calculated by QuantiSeq and MCP-counter.
RESULTS: Compared to BrT, more LvM samples had a high TMB (≥ 10 mutations/Mb) and fewer LvM samples had PD-L1+ expression. Evaluation of the TME revealed that LvM sites harbored lower infiltration of adaptive immune cells, such as CD4+, CD8+, and regulatory T-cells compared with the BrT foci. We saw differences in innate immune cell infiltration in LvM compared to BrT, including neutrophils and NK cells.
CONCLUSIONS: LvMs are less likely to express PD-L1+ tumor cells but more likely to harbor high TMB as compared to BrTs. Unlike AxMs, LvMs represent a more immunosuppressed TME and demonstrate lower gene expression associated with adaptive immunity compared to BrTs. These findings suggest biopsy site be considered when interpreting results that influence ICI use for treatment and further investigation of immune composition and biomarkers expression by metastatic site.
PURPOSE:To produce the title material which is flexible and has a smooth surface and excellent anticoagulating properties, by saponifying the surface of a specified polyurethane (urea) molding, neutralizing it and bonding it to heparin. CONSTITUTION:A compd. contg. two hydroxyl groups and one ester group per molecule (e.g. methyl dimethylkolpropionate) or a compd. contg. two amino groups andone ester group per molecule (e.g. methyl ester of L-lysine) and a diisocyanate (e.g. ethylene diisocyanate) are subjected to a polyaddition reaction in the presence or absence of a polyester diol having an MW of 200-800 to obtain a polyurethane (urea). The polyurethane (urea) is molded into a film or tube, which is them immersed in an alkaline soln. to saponify it. The saponified molding is immersed in an acidic soln. to neutralize it, and the neutralized molding is bonded to heparin.
The invention discloses an American cockroach medicinal composition for curing gastritis and peptic ulcers. The medicinal composition is mainly prepared from an active ingredient mixture prepared by mixing an American cockroach extract, white peony root, bletilla, radix pseudo-ginseng, liquoric root, Indian buead, rhizoma corydalis, cuttlebone and belladonna extract. The weight part ratio of the American cockroach extract to the white peony root to the bletilla to the radix pseudo-ginseng to the liquoric root to the Indian buead to the rhizoma corydalis to the cuttlebone to the belladonna extract is equal to 0.8-1. 2g :1-10g:1-10g:0.5-6g:0.25-6g:0.25-10g:0.5-6g:0.83-6g:5-60mg. A preparation method of the American cockroach medicinal composition for curing the gastritis and the peptic ulcers comprises the following steps of: preparing the American cockroach extract, weighting, decocting, and mixing active ingredients, and preparing medicaments. The medicinal composition has simple preparation method, fully exerts effects of the American cockroach extract, and effectively improves curative effects on the gastritis and the peptic ulcers.
This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count \<30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.

The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.
PROBLEM TO BE SOLVED: To obtain a flavano-lignan preparation capable of guaranteeing sufficient usability for organisms and absorption ratio through the body of an individual. SOLUTION: An alcoholic aqueous solution of a pharmacological carrier and a wetting agent is obtained. Flavano-lignan is suspended or heated to a boiling temperature. Otherwise flavano-lignan and the wetting agent are suspended in an alcohol and heated with stirring until a clear solution is formed and the prepared suspension is mixed with an aqueous solution of the pharmacological carrier. The obtained mixture is heated with stirring until a clear solution is formed. Successively the obtained clear solution is concentrated, filtered and a formed coprecipitate is dried under vacuum. The medicine is not observed to have harmful actions and a silibinin coprecipitate is used in the case of high dose in the same manner as that of silibinin and silymarin.
Apparatus and associated methods relate to a neuro-harmonizing system (NHS). In an illustrative example, the NHS may automatically generate a neuro-harmonizing audible feedback package to induce a non-therapeutic state. The NHS, for example, may receive an input signal from a user device. For example, the NHS may apply the input signal to a state prediction model to identify a current state of the user device. A set of target criterion, for example, may be generated based on the current state. For example, the set of target criterion including transformation parameters configured to transform the input signal into a new signal for inducing a dynamically generated target state based on a user profile. The NHS may, for example, generate an audible feedback package as a function of the input signal and the set of target criterion. Various embodiments may advantageously induce the dynamically generated target state.
For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
BACKGROUND: Abnormal lipid metabolism has recently been reported as a crucial signature of idiopathic pulmonary fibrosis (IPF). However, the origin and biological function of the lipid and possible mechanisms of increased lipid content in the pathogenesis of IPF remains undetermined.
METHODS: Oil-red staining and immunofluorescence analysis were used to detect lipid accumulation in mouse lung fibrosis frozen sections, Bleomycin-treated human type II alveolar epithelial cells (AECIIs) and lung fibroblast. Untargeted Lipid omics analysis was applied to investigate differential lipid species and identified LysoPC was utilized to treat human lung fibroblasts and mice. Microarray and single-cell RNA expression data sets identified lipid metabolism-related differentially expressed genes. Gain of function experiment was used to study the function of 3-hydroxy-3-methylglutaryl-Coa Synthase 2 (HMGCS2) in regulating AECIIs lipid metabolism. Mice with AECII-HMGCS2 high were established by intratracheally delivering HBAAV2/6-SFTPC- HMGCS2 adeno-associated virus. Western blot, Co-immunoprecipitation, immunofluorescence, site-directed mutation and flow cytometry were utilized to investigate the mechanisms of HMGCS2-mediated lipid metabolism in AECIIs.
RESULTS: Injured AECIIs were the primary source of accumulated lipids in response to Bleomycin stimulation. LysoPCs released by injured AECIIs could activate lung fibroblasts, thus promoting the progression of pulmonary fibrosis. Mechanistically, HMGCS2 was decreased explicitly in AECIIs and ectopic expression of HMGCS2 in AECIIs using the AAV system significantly alleviated experimental mouse lung fibrosis progression via modulating lipid degradation in AECIIs through promoting CPT1A and CPT2 expression by interacting with PPARα.
CONCLUSIONS: These data unveiled a novel etiological mechanism of HMGCS2-mediated AECII lipid metabolism in the genesis and development of pulmonary fibrosis and provided a novel target for clinical intervention.
Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
Pharmacokinetics and Metabolism

Ethacrynate sodium acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynate sodium inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynate sodium is effective in many patients who have significant degrees of renal insufficiency (see WARNINGS concerning deafness). Ethacrynate sodium has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.

The electrolyte excretion pattern of ethacrynic acid varies from that of the thiazides and mercurial diuretics. Initial sodium and chloride excretion is usually substantial and chloride loss exceeds that of sodium. With prolonged administration, chloride excretion declines, and potassium and hydrogen ion excretion may increase. Ethacrynate sodium is effective whether or not there is clinical acidosis or alkalosis.

Although ethacrynate sodium, in carefully controlled studies in animals and experimental subjects, produces a more favorable sodium/potassium excretion ratio than the thiazides, in patients with increased diuresis excessive amounts of potassium may be excreted.

Onset of action is rapid, usually within 30 minutes after an oral dose of Ethacrynic Acid Tablets USP or within 5 minutes after an intravenous injection of ethacrynate sodium. After oral use, diuresis peaks in about 2 hours and lasts about 6 to 8 hours.

The sulfhydryl binding propensity of ethacrynic acid differs somewhat from that of the organomercurials. Its mode of action is not by carbonic anhydrase inhibition.

Ethacrynic acid does not cross the blood-brain barrier.